OracleBio contributed to a Discovery R&D program for a biopharmaceutical company focused on small molecule drugs for oncology.
By utilising Tumor Microarrays (TMA) and quantitative digital pathology, we supported the data-driven decision-making process for guiding clinical studies disease selection by leveraging image analysis to quantify the expression of Arginase-1 +ve cells (# mm2) across various cancer TMAs
Click here to view the Case Study poster and learn more about the aim and outcome.
To find out more about OracleBio’s digital pathology services to support Immuno-oncology R&D, please click here.
To keep up to date with all OracleBio news and publications, please follow us on LinkedIn by clicking the button below: